EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access

Efficacy and Safety of Bempedoic Acid in Patients Aged ≥75 Years Stratified by Varying Statin Exposure: Results From Phase 3 Studies of Bempedoic Acid

G B John Mancini iD, A Michael Lincoff iD, Anne C Goldberg, Christine Broestl, Na Li iD, P Barton Duell iD, Ulrich Laufs iD, Alberico L Catapano iD, Lawrence A Leiter iD, Maciej Banach iD, Peter M Herout iD, Stephen J Nicholls iD und 4 weitere

Journal of the American Heart Association · 07.07.2026 · 15 (13)

DOI: 10.1161/jaha.125.047897 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of the American Heart Association, erschienen am 07.07.2026. Verfasst von G B John Mancini und 15 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Cardiovascular Innovation Vancouver Hospital Vancouver BC Canada. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dicarboxylic Acids, Fatty Acids, Cardiovascular Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lowering low‐density lipoprotein cholesterol (LDL‐C) reduces the risk of major vascular events across all age groups. We analyzed phase 3 studies of bempedoic acid to characterize the safety and efficacy in patients aged ≥75 years with and without a concomitant statin.

Methods

Post hoc analysis of bempedoic acid in high‐risk patients with cardiovascular disease by age from phase 3 placebo‐controlled, randomized clinical trials: two 52‐week primary hyperlipidemia studies with maximal background statin (“max‐statins pool”), and 1 cardiovascular outcomes trial (“statin‐intolerant pool”). Efficacy (LDL‐C, non–high‐density lipoprotein cholesterol, total cholesterol, high‐sensitivity C‐reactive protein) and safety were evaluated.

Results

The max‐statins pool included 3009 (2010 bempedoic acid, 999 placebo) patients. The statin‐intolerant pool included 13 970 patients (6992 bempedoic acid, 6978 placebo). In total 7022 patients were aged 18 to

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsDicarboxylic AcidsFatty AcidsCardiovascular DiseasesHumansAgedTreatment OutcomeMaleFemaleCholesterol, LDLAged, 80 and overAge FactorsBiomarkersDrug Therapy, Combination

Stichwörter der Autor:innen

LDL‐Cbempedoic acidelderlymuscle painsafetystatinstatin intolerant

Substanzen

8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acidHydroxymethylglutaryl-CoA Reductase InhibitorsDicarboxylic AcidsFatty AcidsCholesterol, LDLBiomarkers

Autor:innen und Institutionen

  • Centre for Cardiovascular Innovation Vancouver Hospital Vancouver BC Canada.
  • Department of Cardiovascular Medicine Cleveland Clinic Foundation Cleveland OH USA.
  • Washington University St. Louis MO USA.
  • Esperion Therapeutics, Inc. Ann Arbor MI USA.
  • Center for Preventive Cardiology, Knight Cardiovascular Institute Oregon Health and Science University Portland OR USA.
  • Clinic for Cardiology University of Leipzig Medical Center Leipzig Germany.

ORCID-Profile: G B John Mancini, A Michael Lincoff, Na Li, P Barton Duell, Ulrich Laufs, Alberico L Catapano, Lawrence A Leiter, Maciej Banach, Peter M Herout, Stephen J Nicholls, Steven E Nissen, Debabrata Mukherjee

Zitieren

APA

Mancini, G. B. J., Lincoff, A. M., Goldberg, A. C., Broestl, C., Li, N., Duell, P. B., Laufs, U., Catapano, A. L., Leiter, L. A., Banach, M., Herout, P. M., Nicholls, S. J., Bloedon, L., Powell, H. A., Nissen, S. E., & Mukherjee, D. (2026). Efficacy and Safety of Bempedoic Acid in Patients Aged ≥75 Years Stratified by Varying Statin Exposure: Results From Phase 3 Studies of Bempedoic Acid. Journal of the American Heart Association, 15(13). https://doi.org/10.1161/jaha.125.047897

Vancouver

Mancini GBJ, Lincoff AM, Goldberg AC, Broestl C, Li N, Duell PB, et al. Efficacy and Safety of Bempedoic Acid in Patients Aged ≥75 Years Stratified by Varying Statin Exposure: Results From Phase 3 Studies of Bempedoic Acid. Journal of the American Heart Association. 2026;15(13). doi:10.1161/jaha.125.047897

BibTeX
@article{Mancini2026,
  author = {Mancini, G B John and Lincoff, A Michael and Goldberg, Anne C and Broestl, Christine and Li, Na and Duell, P Barton and Laufs, Ulrich and Catapano, Alberico L and Leiter, Lawrence A and Banach, Maciej and Herout, Peter M and Nicholls, Stephen J and Bloedon, LeAnne and Powell, Heather A and Nissen, Steven E and Mukherjee, Debabrata},
  title = {Efficacy and Safety of Bempedoic Acid in Patients Aged ≥75 Years Stratified by Varying Statin Exposure: Results From Phase 3 Studies of Bempedoic Acid},
  journal = {Journal of the American Heart Association},
  year = {2026},
  volume = {15},
  number = {13},
  doi = {10.1161/jaha.125.047897}
}
Kostenlos starten →